AVENUE THERAPEUTICS, INC.: 10-Q filed 2023-11-13
What AVENUE THERAPEUTICS, INC. reported in its quarterly report filed 2023-11-13 (fiscal Q3 2023): 25 published measures, 74 facts as tagged in accession 0001437749-23-031621.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-13
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001437749-23-031621 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AVENUE THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 502,000 | USD | |
| At 2022-12-31 | 6,845,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 5,024,000 | USD | |
| At 2022-12-31 | 3,579,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -3,650,000 | USD | |
| At 2022-12-31 | 3,905,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 161,000 | USD | |
| At 2022-12-31 | 6,708,000 | USD |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -7,127,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -3,427,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 3,580,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -119,000 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -3,000,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 0 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -91,568,000 | USD | |
| At 2022-12-31 | -80,551,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 8,114,155 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 7,155,050 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 1,465,691 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 1,441,542 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 8,200,069 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 7,155,050 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 1,465,691 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 1,441,542 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 0.06 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -1.54 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.45 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -2.86 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 0.06 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -1.54 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.45 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -2.86 | USD/shares | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 599,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 637,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -2,068,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -12,421,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -663,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -4,131,000 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 5,024,000 | USD | |
| At 2022-12-31 | 3,579,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 296,000 | USD | |
| At 2022-12-31 | 129,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 907,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 5,149,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 194,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 2,153,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 8,964,222 | shares | |
| At 2022-12-31 | 4,773,841 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 87,917,000 | USD | |
| At 2022-12-31 | 84,456,000 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -4,522,000 | USD | |
| At 2023-06-30 | -6,146,000 | USD | |
| At 2022-12-31 | 3,266,000 | USD | |
| At 2022-09-30 | -39,000 | USD | |
| At 2022-06-30 | 598,000 | USD | |
| At 2021-12-31 | 3,451,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 18,000 | USD | |
| At 2022-12-31 | 137,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 513,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -11,105,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -662,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -4,127,000 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 526,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -11,017,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -662,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -4,127,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,161,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 3,042,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 469,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,978,000 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 2,581,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 1,316,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 1,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 4,000 | USD | 273 |
Inspect the source
- Entity
- AVENUE THERAPEUTICS, INC. / CIK 0001644963
- Captured
- 2026-09-21T17:22:34.978Z
- SEC response SHA-256
d47022f3bdc96d1311ce29c33bf23e1b20c2f92799a4d19cd1fb7cc34ec7feaa
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001644963.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))